{"id":241932,"date":"2026-07-31T08:09:12","date_gmt":"2026-07-31T13:09:12","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/07\/resetting-autoimmune-disease-with-car-cell-therapies"},"modified":"2026-07-31T08:09:12","modified_gmt":"2026-07-31T13:09:12","slug":"resetting-autoimmune-disease-with-car-cell-therapies","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/07\/resetting-autoimmune-disease-with-car-cell-therapies","title":{"rendered":"Resetting autoimmune disease with CAR cell therapies"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/resetting-autoimmune-disease-with-car-cell-therapies.jpg\"><\/a><\/p>\n<p>Pathogenic B cell activation underlies many autoimmune diseases (AIDs), and their depletion is an attractive therapeutic approach. Chimeric antigen receptor (CAR)-expressing cells-initially developed and successfully used to treat certain cancers-are increasingly being developed to selectively deplete B cells and \u2018reset\u2019 the immune system in AIDs. In this Review, we survey this fast-developing field, providing insights on the current unmet needs in the treatment of AIDs and how CAR T cells could address these needs. In particular, we explore the concept of deep B cell depletion, discuss the currently available technologies and review the key targets (CD19 and B cell maturation antigen) relevant for the treatment of AIDs. We summarize current evidence on the efficacy, safety, risks and limitations of autologous and allogeneic CAR T cells in this setting. Finally, we discuss the future outlook-from a technological and clinical standpoint-for development of engineered CAR-expressing cell therapies for AIDs.<\/p>\n<p>\u00a9 2026. Springer Nature America, Inc.<\/p>\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/disclaimer\/\" target=\"_blank\">PubMed Disclaimer<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pathogenic B cell activation underlies many autoimmune diseases (AIDs), and their depletion is an attractive therapeutic approach. Chimeric antigen receptor (CAR)-expressing cells-initially developed and successfully used to treat certain cancers-are increasingly being developed to selectively deplete B cells and \u2018reset\u2019 the immune system in AIDs. In this Review, we survey this fast-developing field, providing insights [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,20],"tags":[],"class_list":["post-241932","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-futurism"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/241932","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=241932"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/241932\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=241932"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=241932"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=241932"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}